Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer’s disease

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Afferent and efferent immunological pathways of the brain. Anatomy, Function and Failure

(2013) R.O. Carare et al.   BRAIN BEHAVIOR AND IMMUNITY

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Correlation of Aβ oligomer levels in matched cerebrospinal fluid and serum samples

(2013) Takashi Kasai et al.   NEUROSCIENCE LETTERS

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid

(2013) Adrianna Z. Herskovits et al.   PLoS One

Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for Aβ oligomers

(2012) Takashi Kasai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid  

(2012) J. J. Iliff et al.   Science Translational Medicine

Naturally Occurring Autoantibodies against  -Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease

(2011) R. Dodel et al.   JOURNAL OF NEUROSCIENCE

High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

(2010) Hiroaki Fukumoto et al.   FASEB JOURNAL

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Seizures in Alzheimer Disease

(2009) Nikolaos Scarmeas et al.   ARCHIVES OF NEUROLOGY

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease

(2008) Alex E. Roher et al.   Alzheimers & Dementia

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING